Figure 3.

Clinical history and sample collection time points of three NSCLC patients Clinical treatments and primary diagnoses of each patient are located on top of the black time arrow which are coloured by treatment type (blue: TKI treatments; green: chemotherapy; pink: trastuzumb; and red: surgery). Disease progressions are indicated by the yellow circle with ‘PD’. The time points of plasma, FFPE or tissue samples collected from each patient are shown along the time arrow. For each detected sample, EGFR-related and ERBB2-related mutations are listed in the box with mutational allele frequencies. ERBB2 exon 16 skipping, both large fragment deletion (ERBB2ΔEx16) and splice site mutations are highlighted in red. EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; FFPE, formalin-fixed paraffin-embedded; PD, progressed disease.